Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21


An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies.

Prémaud A, Filloux M, Gatault P, Thierry A, Büchler M, Munteanu E, Marquet P, Essig M, Rousseau A.

PLoS One. 2017 Jul 3;12(7):e0180236. doi: 10.1371/journal.pone.0180236. eCollection 2017.


Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients.

Daher Abdi Z, Prémaud A, Essig M, Alain S, Munteanu E, Garnier F, Le Meur Y, Marquet P, Rousseau A.

Clin Pharmacol Ther. 2014 Oct;96(4):508-15. doi: 10.1038/clpt.2014.140. Epub 2014 Jun 26.


Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.

Daher Abdi Z, Lavau-Denes S, Prémaud A, Urien S, Sauvage FL, Martin J, Leobon S, Marquet P, Tubiana-Mathieu N, Rousseau A.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1285-93. doi: 10.1007/s00280-014-2466-0. Epub 2014 May 7.


Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach.

Daher Abdi Z, Essig M, Rizopoulos D, Le Meur Y, Prémaud A, Woillard JB, Rérolle JP, Marquet P, Rousseau A.

Pharmacol Res. 2013 Jun;72:52-60. doi: 10.1016/j.phrs.2013.03.009. Epub 2013 Apr 1.


Ciclosporin population pharmacokinetics and Bayesian estimation in thoracic transplant recipients.

Fruit D, Rousseau A, Amrein C, Rollé F, Kamar N, Sebbag L, Redonnet M, Epailly E, Marquet P, Prémaud A.

Clin Pharmacokinet. 2013 Apr;52(4):277-88. doi: 10.1007/s40262-013-0037-x.


Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients.

de Winter BC, Monchaud C, Prémaud A, Pison C, Kessler R, Reynaud-Gaubert M, Dromer C, Stern M, Guillemain R, Knoop C, Estenne M, Marquet P, Rousseau A.

Clin Pharmacokinet. 2012 Jan 1;51(1):29-39. doi: 10.2165/11594050-000000000-00000.


Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients.

Saint-Marcoux F, Vandierdonck S, Prémaud A, Debord J, Rousseau A, Marquet P.

Ther Drug Monit. 2011 Jun;33(3):285-94. doi: 10.1097/FTD.0b013e31821633a6.


Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships.

Prémaud A, Rousseau A, Johnson G, Canivet C, Gandia P, Muscari F, Peron JM, Rostaing L, Marquet P, Kamar N.

Pharmacol Res. 2011 May;63(5):432-8. doi: 10.1016/j.phrs.2011.01.005. Epub 2011 Jan 15.


Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches.

Prémaud A, Weber LT, Tönshoff B, Armstrong VW, Oellerich M, Urien S, Marquet P, Rousseau A.

Pharmacol Res. 2011 Mar;63(3):216-24. doi: 10.1016/j.phrs.2010.10.017. Epub 2010 Nov 5.


Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation.

Benkali K, Rostaing L, Premaud A, Woillard JB, Saint-Marcoux F, Urien S, Kamar N, Marquet P, Rousseau A.

Clin Pharmacokinet. 2010 Oct;49(10):683-92. doi: 10.2165/11535950-000000000-00000.


Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.

Benkali K, Prémaud A, Picard N, Rérolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A.

Clin Pharmacokinet. 2009;48(12):805-16. doi: 10.2165/11318080-000000000-00000.


Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients.

Prémaud A, Rousseau A, Le Meur Y, Venisse N, Loichot C, Turcant A, Hoizey G, Compagnon P, Hary L, Debruyne D, Saivin S, Jacqz-Aigrain E, Marquet P.

Pharmacol Res. 2010 Feb;61(2):167-74. doi: 10.1016/j.phrs.2009.09.006. Epub 2009 Oct 2.


Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients.

Marquet P, Saint-Marcoux F, Prémaud A, Sauvage FL, Jaqz-Aigrain E, Knoop C, Lebranchu Y, Tiberi M, Domke I, Debord J.

Ther Drug Monit. 2009 Aug;31(4):443-50. doi: 10.1097/FTD.0b013e3181a8f0ae.


A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.

Picard N, Prémaud A, Rousseau A, Le Meur Y, Marquet P.

Br J Clin Pharmacol. 2006 Oct;62(4):477-84.


A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.

Prémaud A, Debord J, Rousseau A, Le Meur Y, Toupance O, Lebranchu Y, Hoizey G, Le Guellec C, Marquet P.

Clin Pharmacokinet. 2005;44(8):837-47.


Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods.

Prémaud A, Le Meur Y, Debord J, Szelag JC, Rousseau A, Hoizey G, Toupance O, Marquet P.

Ther Drug Monit. 2005 Jun;27(3):354-61.


Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5.

Picard N, Cresteil T, Prémaud A, Marquet P.

Ther Drug Monit. 2004 Dec;26(6):600-8.


Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, Marquet P.

Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6.


An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.

Prémaud A, Rousseau A, Gicquel M, Ragot S, Manceau J, Laurentie M, Marquet P.

Toxicol Appl Pharmacol. 2002 Sep 15;183(3):189-97.


Supplemental Content

Loading ...
Support Center